Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Lytic Cycle of Bacteriophages
Microorganisms in Medicine and Therapeutics
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Nov 15, 2025

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice
Published on: January 26, 2024
Amanda Carroll-Portillo1, Henry C Lin1,2
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA.
Phage therapy for gut disorders faces challenges with complex microbial shifts. Mucin in the GI tract may enhance phage interactions, offering a potential adjunct for improving phage therapy effectiveness in dysbiosis.
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
08:51Profiling of Permethylated Mucin O-glycans Using Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry
Published on: June 20, 2025
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: